White House: gene-editing research raises serious, urgent questions
This article was originally published in Scrip
Executive Summary
Altering the human germline for clinical purposes is a line that "should not be crossed at this time," White House Office of Science and Technology Policy Director Dr John Holdren said on 26 May, declaring that a robust review of the ethical issues involved must first be completed.